All In Biotech

NDA 021337 · Msd Sub Merck

Invanz

Ertapenem Sodium · Intramuscular, Intravenous

Novel

Last checked: Nov 20, 2026Latest source record: Mar 17, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Nov 21, 2001

Approved uses

4

Original approval plus efficacy supplements

Registered trials

76

28 Phase 3, 6 recruiting

FAERS reports

7,465

6,366 serious, 639 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 2, 2026.

Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: Complicated intra-abdominal infections. ( 1.1 ) Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) Community-acquired pneumonia. ( 1.3 ) Complicated urinary tract infections including pyelonephritis. ( 1.4 ) Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ertapenem for injection and other antibacterial drugs, ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) 1.1 Complicated Intra-Abdominal Infections Ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to Escherichia coli , Clostridium clostridioforme , Eubacterium lentum , Peptostreptococcus species, Bacteroides fragilis , Bacteroides distasonis , Bacteroides ovatus , Bacteroides thetaiotaomicron , or Bacteroides uniformis . 1.2 Complicated Skin and Skin Structure Infections, Including Diabetic Foot Infections without Osteomyelitis Ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections,...

Mechanism: Ertapenem sodium is a carbapenem antibiotic [see Clinical Pharmacology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • INVANZ · ERTAPENEM SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INTRAMUSCULAR, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ertapenem" as an intervention, any sponsor and status, largest first.

All 76 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,161
  • macular degeneration808
  • off label use539
  • pyrexia467
  • confusional state441
  • product use in unapproved indication434
  • nausea397
  • pain345
  • weight decreased274
  • malaise271
  • anaemia268
  • hallucination266

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004115
200560
200693
2007117
2008125
2009103
2010117
2011138
2012246
2013287
2014279
2015347
2016318
2017284
2018425
2019429
2020483
2021768
2022633
2023585
2024589
2025538
2026386

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Invanz (Ertapenem Sodium)

2024 spending

$11K

Beneficiaries

26

34 claims

Per beneficiary

$415

$46.53 per unit

View as table
YearSpending
2020$463,297
2021$187,177
2022$96,539
2023$13,802
2024$10,795

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 151 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.